1. Home
  2. Company search

Company search

KOBE Life Science Cluster Company List

Business Expansion
on Kobe's Port Island

370

companies

as of February 29, 2024

Companies are divided into categories by their major business field on Kobe Port Island. In the case they have other business fields, it is shown in the minor field.» List of KBIC companies(PDF)

≫ StartupsStartups Company List

Search by Company name or Keyword

Bacchus Bio innovation Co., Ltd.

Major field:Material and Chemical Products

Miner field:Contract Research

Miner field:Production of Drugs and Quasi Drugs

Integrated biofoundry

Overview

Utilizing biotechnology (genome editing technology, DNA synthesis technology, etc.) and digital technology (IT and AI), we can design microorganisms to produce new substances (Design), create the designed microorganisms (Build), select excellent microorganisms from among the created microorganisms (Test), and analyze the measured data from the constructed microorganisms (Learn). The DBTL flow is rotated at a high speed to enhance functions and add new functions to microorganisms, including the integrated analysis of measured data (Learn). We can efficiently produce various substances such as pharmaceutical raw materials, fuels, plastics, food additives, and cosmetic raw materials.

Product / Service / PR

    In health and medical industry, even if a drug candidate with excellent efficacy and effectiveness is discovered, product development is often suspended because it cannot be mass-produced or commercialized using conventional chemical synthesis and cultivation methods. Our technology enables the efficient production of pharmaceutical raw materials or intermediates of microbial origin, and contributes to the reduction of drug prices of existing products.
Address: Head office location
1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo 657-0013, Japan 
Bio-Foundry
6-3-7 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan Creative Lab Kobe 505 
(Contact Person Shogo Harumoto)
TEL: +81-78-599-5717 FAX: +81-78-599-5718
Web site: https://www.b2i.co.jp/ E-mail: info@b2i.co.jp

Cyto-Facto Inc.

Major field:Regenerative Medicine

Miner field:Contract Research

Miner field:Production of Drugs and Quasi Drugs

Specialized in manufacturing cell and gene products as CDMO

Overview

Services we provide in the field of cell & gene therapy
1. Contracted manufacturing of commercial products (CMO)
2. Process development and manufacturing of clinical products (CDMO)
3. Quality control testing of CGT products for commercial, clinical and research use
4. Development, sales, and service business of manufacturing management systems
5. Consultation for regulatory issues

Product / Service / PR

    Cyto-Facto (its predecessor, the RDC of the FBRI) is the first Asian company to manufacture commercial CAR-T products in compliance with PIC/S GMP. Cyto-Facto has accumulated experience in manufacturing technology know-how and has launched several cell & gene manufacturing pipelines, including CAR-T, iPSC-based cells and mesenchymal stem cells (MSCs) of various developmental stages.
Address: TRI 3F 1-5-4 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047 Japan  (Contact Person Takeshi Itoh)
TEL: +81-78-306-0681
Web site: https://www.cytofacto.com/eng/ E-mail: info@cytofacto.com

HEALIOS K.K.

Major field:Regenerative Medicine

Research, development, manufacture of cell therapy products and regenerative medicine products

Overview

Raising our mission, “To be the change in an ever evolving world through enrichment of living”, HEALIOS was established in 2011 via Riken Venture system.
We are dedicated to develop promising medicines to heal and bring hope to those worldwide who are suffering from incurable diseases by making use of the regenerative power.

Product / Service / PR

    [Somatic stem cell regenerative medicine]
    Development of regenerative medicine for ischemic stroke and Acute Respiratory Distress Sydrome (ARDS) in Japan using MultiStem®, products developed by Athersys, Inc.
    [iPSC regenerative medicine]
    Development of Treatments for Age-Related Macular Degeneration (AMD) involving transplantation of iPS cell-derived retinal pigment epithelial (RPE) cells.
    Development of Organ Bud Transplantation Therapy involving a technology to create functional human organs using iPS cells.
Address: Kobe KIMEC Center Building 3F, 1-5-2 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan 
Web site: https://www.healios.co.jp/en/ E-mail: info@healios.jp

Hirosaki Life science Innovation, Inc.

Major field:Regenerative Medicine

Miner field:Drug Discovery

Development, manufacturing, and marketing of regenerative medicine products

Overview

Development, manufacturing and supply of regenerative and other medical products

Product / Service / PR

    Based on the results of an investigator-led clinical trial conducted by Kobe University and Foundation for Biomedical Research and Innovation (FBRI), Hirosaki Life science Innovation, Inc. is preparing for the pivotal clinical trial of IK-01, which is a collagen matrix containing chondrocytes indicated for focal articular cartilage defects in the knee, to obtain the marketing authorization.
Address: Kojimachi 285 Building 2F, Kojimachi 2-8-5,Chiyodaku Tokyo, 102-0083 Japan  (Contact Person Youichiro Machida)
TEL: +81-36-457-9861 FAX: +81-36-261-4445
Web site: http://hirosaki-li.co.jp/company.html E-mail: y-machida@hirosaki-li.co.jp

Sumitomo Pharma Co., Ltd.

Major field:Drug Discovery

Miner field:Regenerative Medicine

Research of regenerative medicine and cell therapy

Overview

The Sumitomo Pharma Group sets the pharmaceutical business as its core activity but also deploys other operations covering food ingredients, food additives and chemical product materials, animal health products, diagnostics and research materials. In order to deliver innovative and useful pharmaceuticals to people worldwide as well as in Japan we make every effort in applying advanced R&D to all of our new pharmaceuticals. Aiming at improving customer satisfaction we also provide all relevant information with regard to our drug products.

Product / Service / PR

    We position the Regenerative Cellular medicine area in addition to the Psychiatry & Neurology and the Oncology areas as our focus therapeutic areas where we are targeting the creation of innovative pharmaceuticals. Here at Regenerative & Cellular Medicine Kobe Center, we are focusing on development research and manufacturing study of the cellular medicines those are derived from human iPS cells.
Address: Kobe KIMEC Center Building 5th Fl. 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe, Hyogo 650-0047,Japan  (Contact Person Atsushi Ikeda)
TEL: +81-078-306-2170 FAX: +81-078-303-4040
Web site: https://www.sumitomo-pharma.com E-mail: ml-smp-racmok@sumitomo-pharma.co.jp